Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | 2020 UK AML trials update

Charles Craddock • 18 Apr 2020
Acute Myeloid Leukemia Leukemia Antibodies Azacitidine Daratumumab

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, discusses the research underway through the UK IMPACT stem cell transplantation cooperative, including the PRO-DLI trial (NCT02856464), investigating whether prophylactic donor lymphocyte infusions (DLI) delivered as part of a planned schedule improves disease-free survival in patients with myeloid malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Charles Craddock

2:14
Addressing the high rate of disease relapse following alloSCT in patients with AML
Charles Craddock • 10 Dec 2023
1:32
Stem cell transplantation conditioning in AML: making the decision between MAC and RIC
Charles Craddock • 10 Dec 2023
1:22
The UK Impact Transplant Trials Network: a national strategy to accelerate delivery of alloSCT RCTs
Charles Craddock • 10 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals